Fibroblast Growth Factor Receptor 1-4 Genetic Aberrations as Clinically Relevant Biomarkers in Squamous Cell Lung...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacogenomics

Background:

• Squamous non-small cell lung cancer (Sq-NSCLC) may benefit from fibroblast growth factor receptor (FGFR) inhibitors (FGFRis).
• Accurate patient selection for targeted therapies like FGFRis requires robust predictive biomarkers.
• FGFR aberrations, including alterations, amplification, and overexpression, are found in Sq-NSCLC, but their clinical utility is not fully established.

Purpose of the Study:

• To investigate FGFR aberrations as predictive biomarkers for FGFR-targeting agents in Sq-NSCLC.
• To evaluate the potential of FGFR mRNA overexpression, mutations, and fusions in patient stratification.
• To discuss known and potential molecular mechanisms of FGFR inhibitor resistance.

Main Methods:

• Review of existing literature on FGFR aberrations in Sq-NSCLC.
• Analysis of clinical data from small patient cohorts.
• Exploration of molecular profiling techniques for biomarker discovery.

Main Results:

• FGFR1 amplification showed unreliable predictive value.
• FGFR mRNA overexpression, mutations, and fusions are identified as promising predictive biomarkers.
• Current discriminatory power of these biomarkers is insufficient, necessitating larger clinical studies.

Conclusions:

• FGFR aberrations, particularly mRNA overexpression, mutations, and fusions, hold promise as predictive biomarkers for FGFRis in Sq-NSCLC.
• Further research with larger patient groups is required to validate these biomarkers and improve patient selection.
• Understanding resistance mechanisms is crucial for optimizing FGFR inhibitor therapy in Sq-NSCLC.